BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Fechado

SetorSaúde

92.54 -0.88

Visão Geral

Variação de preço das ações

24h

Atual

Mín

92.18

Máximo

94.26

Indicadores-chave

By Trading Economics

Rendimento

-2.3B

499M

Vendas

-6.5B

7.6B

P/E

Médio do Setor

20.663

57.333

EPS

1.31

Rendimento de Dividendos

4.32

Margem de lucro

6.539

Funcionários

82,878

EBITDA

-3.7B

563M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+22.28% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.32%

2.63%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-20B

111B

Abertura anterior

93.42

Fecho anterior

92.54

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Sanofi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 08:52 UTC

Ganhos

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24 de abr. de 2025, 05:44 UTC

Ganhos

Sanofi Sales, Profit Beat Expectations

9 de abr. de 2025, 06:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20 de mar. de 2025, 06:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24 de abr. de 2025, 12:54 UTC

Conversa de Mercado
Ganhos

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24 de abr. de 2025, 10:06 UTC

Conversa de Mercado
Ganhos

Sanofi Starts the Year Strong -- Market Talk

10 de abr. de 2025, 12:06 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10 de abr. de 2025, 09:10 UTC

Ações em Alta

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9 de abr. de 2025, 10:49 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9 de abr. de 2025, 08:19 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9 de abr. de 2025, 06:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9 de abr. de 2025, 06:46 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4 de abr. de 2025, 09:07 UTC

Ações em Alta

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3 de abr. de 2025, 07:51 UTC

Conversa de Mercado

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 de abr. de 2025, 13:44 UTC

Conversa de Mercado

Santander Push Into Canada on the Cards -- Market Talk

2 de abr. de 2025, 09:27 UTC

Ações em Alta

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 de mar. de 2025, 06:19 UTC

Conversa de Mercado
Ganhos

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 de mar. de 2025, 10:08 UTC

Conversa de Mercado

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 de mar. de 2025, 09:00 UTC

Principais Notícias

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 de mar. de 2025, 06:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 de mar. de 2025, 06:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 de mar. de 2025, 06:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi to Pay $600M Upfront

20 de mar. de 2025, 06:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 de mar. de 2025, 06:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 de mar. de 2025, 09:33 UTC

Ações em Alta

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 de mar. de 2025, 23:00 UTC

Principais Notícias

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 de mar. de 2025, 09:50 UTC

Ganhos

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 de mar. de 2025, 09:49 UTC

Ganhos

Santander Increased 2024 Cash Payments by 19%

24 de fev. de 2025, 08:56 UTC

Conversa de Mercado
Ganhos

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 de fev. de 2025, 08:30 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Comparação entre Pares

Variação de preço

Sanofi SA Previsão

Preço-alvo

By TipRanks

22.28% parte superior

Previsão para 12 meses

Média 114.144 EUR  22.28%

Máximo 127 EUR

Mínimo 83.729 EUR

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Sanofi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

14 ratings

10

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

91.62 / 93.4Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.